Mainz Biomed B.V.
Mainz Biomed B.V. (MYNZ) Financial Performance & Income Statement Overview
Analyze Mainz Biomed B.V. (MYNZ) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Mainz Biomed B.V. (MYNZ) Income Statement & Financial Overview
View the income breakdown for Mainz Biomed B.V. MYNZ across both annual and quarterly reports.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $373218.00 | $520773.00 | $214761.00 | $181669.00 |
| Cost of Revenue | $117373.00 | $201735.00 | $80027.00 | $94483.00 |
| Gross Profit | $255845.00 | $319038.00 | $134734.00 | $87186.00 |
| Gross Profit Ratio | $0.69 | $0.61 | $0.63 | $0.48 |
| R&D Expenses | $2.60M | $3.24M | $2.00M | $1.85M |
| SG&A Expenses | $5.89M | $6.88M | $4.49M | $3.87M |
| Operating Expenses | $9.14M | $10.13M | $6.49M | $5.73M |
| Total Costs & Expenses | $9.26M | $10.33M | $6.81M | $5.82M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1.08M | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $680889.00 | $336148.00 | $239616.00 | $203574.00 |
| EBITDA | -$10.09M | -$9.47M | -$4.69M | -$5.44M |
| EBITDA Ratio | -$27.03 | -$18.19 | -$21.86 | -$29.93 |
| Operating Income | -$8.89M | -$9.81M | -$6.59M | -$5.64M |
| Operating Income Ratio | -$23.81 | -$18.83 | -$30.69 | -$31.05 |
| Other Income/Expenses (Net) | -$1.74M | -$1.22M | $1.41M | -$659119.00 |
| Income Before Tax | -$10.63M | -$11.02M | -$5.18M | -$6.30M |
| Income Before Tax Ratio | -$28.47 | -$21.17 | -$24.14 | -$34.68 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$10.63M | -$11.02M | -$5.18M | -$6.30M |
| Net Income Ratio | -$28.47 | -$21.17 | -$24.14 | -$34.68 |
| EPS | -$2.63 | -$19.73 | -$0.29 | -$0.39 |
| Diluted EPS | -$2.63 | -$19.73 | -$0.29 | -$0.39 |
| Weighted Avg Shares Outstanding | $968234.00 | $558751.00 | $17.68M | $15.97M |
| Weighted Avg Shares Outstanding (Diluted) | $968234.00 | $558751.00 | $17.68M | $15.97M |
Over the last four quarters, Mainz Biomed B.V.'s revenue moved from $181669.00 in Q3 2023 to $373218.00 in Q4 2024. Operating income in Q4 2024 was -$8.89M, with a strong operating margin of -2381%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Mainz Biomed B.V. remained robust at -$10.09M, reflecting operational efficiency. Net income rose to -$10.63M, with an EPS of -$2.63. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan